By a combination of all these properties, T22 ensures the architectonic stability of the protein material in the bloodstream and allows a selective intracellular accumulation of T22-empowered protein-only nanoparticles and associated drugs into CXCR4-overexpressing cancer stem cells [17,18,19]. This evidence concerns the gene CXCR4 and cancer.